ZEISS supports the transition of spatial biology to clinical research
Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation
- Comprehensive solution portfolio – from multiplex immunofluorescence (mIF) staining reagents to spatial image analyses – designed to meet the challenges of clinical research
- Highly controlled and fully automated operation from slide to report, with optional Laboratory Information Management System (LIMS) integration
- Exceptional speed, high throughput, and reproducible results support drug development as well as translational and clinical biomarker research
Today marks the global launch of ZEISS Axioscan 7 spatial biology. The newly optimized slide scanner is the central component of a novel analytical workflow solution portfolio – spanning from sample staining to result reports – tailored to spatial biology applications in clinical research environments.
Spatial biology describes a highly active area of research which enables in-depth characterization of cellular interactions in their native tissue environment and has significantly fueled our understanding of various diseases and areas of therapy, especially in immuno-oncology. With the transition of this highly promising technology from basic research towards routine clinical application, the demands have significantly increased. Scientists in contract research organizations (CROs), the pharmaceutical industry, biotechnology as well as other related high-throughput laboratories are now facing new challenges when applying spatial biology to support drug development in biomarker discovery, translational research, and clinical trial monitoring. Existing methods are complicated, difficult to scale, and oftentimes do not provide data of sufficient quality or reproducibility to support their work.
“ZEISS has long-standing expertise in providing robust and high-quality solutions for demanding research environments,” says Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions. “We are now providing an end-to-end workflow to bring this quality to high-throughput applications. Automation, standardization, ease-of-use, and seamless integration of AI-powered image analysis enable spatial biology at scale.”
Automated scanning of up to 100 slides in a single run
ZEISS Axioscan 7 spatial biology is newly optimized for multiplex immunofluorescence (mIF) imaging across large cohorts of samples. It allows up to eight fluorescence-stained biomarkers to be studied at the same time and can fully automatically scan up to 100 samples in a single run, significantly enhancing research throughput. A carefully coordinated selection of hardware and software solutions contributes to superior reproducibility of the images and data for longitudinal and multi-site studies.
mIF staining reagents
The OmniVUE™ reagents from our partner Ultivue leverage advanced DNA-based amplification technology designed for high specificity and dynamic range, which can be optimally recorded with the ZEISS Axioscan 7 spatial biology. Ultivue offers ready-to-use validated assays paired with co-optimized analysis algorithms, eliminating the need for assay development and providing instructive data as much as three times faster than competing technologies. The improved instrument and workflow are fully compatible with a broad range of assays, including various mIF reagents, standard IHC, and H&E. Samples stained with different assays can easily be imaged automatically in the same batch.
Fully automated image analysis
The integrated solution by our partner Mindpeak makes image analyses for mIF samples as straightforward as for scoring of standard immunohistochemistry (IHC). Mindpeak’s leading technology for clinical-grade IHC image analysis and their streamlined cloud platform now enable the efficient analysis of IHC and mIF-stained tissue images generated by ZEISS Axioscan 7 spatial biology. Spatial biology assays can be paired with pre-optimized analytics that are automatically run after image acquisition, enabling efficient review processes and significantly accelerating the time to results.
Services for advanced lab automation
The new spatial biology workflow improves consistency and operational efficiency through an intuitive workflow manager software. Customization services are available to adapt the workflow to individual laboratory processes and to support integration with Laboratory Information Management Systems (LIMS).
AI-powered scanning and image analysis routines can be fully automated, documented, and controlled to meet lab-specific requirements, reducing the need for manual steps and supporting increased productivity and reproducibility. This enables spatial biology assays to be implemented as part of routine applications, even at high volumes ranging from hundreds to thousands of samples per day.
The solution is available both as a standalone offering and as an upgrade for existing ZEISS Axioscan 7 systems, providing flexible options for implementation and enhanced operational efficiency.
For more information, click here.
Press contact
ZEISS Research Microscopy Solutions
Vybhav Sinha
Phone: +49 3641 64 3949
Email: press.microscopy@zeiss.com
www.zeiss.com/newsroom
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous
fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena,
the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com
ZEISS Research Microscopy Solutions
ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.
Further information at www.zeiss.com/microscopy
Attachments
- 有机产业出“黑马”全绿康获多项殊荣
- 总统牌即食燕窝 | 顺时而养,觅味秋食
- 临商银行成都路支行多措并举普及金融基础知识
- WS协议号购买指南:选择WhatsApp业务的全球混合协议号
- SLB获得Petrobras的Buzios油田的三份完井合同
- 醉佳名酒汇:探索酒类文化,品味生活之美
- 达势股份(1405.HK)逆势实现全面盈利 收入达到两位数增长
- 趣宠会专访 | 瑞派宠物医院轮值总裁胡文强:锁定市场核心突破口,蓄力全方位数智进化
- 学位有限|2024-2025学年加入烟台耀华
- UIM E1 La Belle Classe Academy by YCM: a pioneering Pilot Academy
- 张宝文‖大雅正声--当代中国画学术中坚六十家提名展
- American Energy Storage Innovations Secures Major Purchase Order for TeraStor Systems from Solway De
- 坚持创新驱动,澳柯玛以新质生产力推动产业发展
- 飞鹤奶粉星飞帆卓睿优质配方守护宝宝健康成长!
- 不止防爆四足,七腾机器人全新轮式产品解锁全新巡检场景解决方案
- 文女士引领乡村振兴新篇,互联网+赋能农业新飞跃!
- instagram引流新方式:群发助手助你打破传统引流方法!
- 锦州黑山县“老秋二手车”和它的“万元、亲民”小汽车
- VCI Global Secures US$12 Million Contract With Datanex for AI-Powered Digital Marketing Solutions Th
- 尚至医疗新战略融资 上海生物医药基金领投 日本三井及镁信健康跟投
- Ins打粉营销软件,Instagram群发工具,共同助你实现市场突围!
- Spine-Tingling “Chains of Eternity” Seasonal Content Update for The Multi-Award-Winning AFK Journey
- 风劲帆满 踔厉奋发|第15届上海国际餐饮食材展览会8月28日上海新国际博览中心盛大开幕!
- 跨越山海,中欧对话-AutoSec Europe 2025欧洲汽车网络安全及数据安全峰会将在德国举办
- “优泰学院——基层医生内分泌规范诊疗提升项目”全国启动十省市共筑糖尿病防治新防线
- 【昆娜宸星学院】第六届“全球国潮文化艺术节”明星嘉宾祝贺(选集)
- 电影《古董计中计之龙璧之战》开播 石雨晴担任女主惊艳上线
- CSG和Cellusys推动漫游创新新时代
- Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK
- Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olver
推荐
-
新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
-
周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
-
看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
-
奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
-
大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
-
透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
-
中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
-
国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
-
私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
-
男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯